Dr. Timothy J. Pluard, MD - Kansas City ...

Dr. Timothy Pluard

Claim this profile

Saint Luke's Cancer Institute LLC

Studies Breast Cancer
Studies Cancer
13 reported clinical trials
23 drugs studied

Area of expertise

1Breast Cancer
Timothy Pluard has run 10 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Cancer
Timothy Pluard has run 4 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
MMR positive

Affiliated Hospitals

Image of trial facility.
Saint Luke's Cancer Institute LLC
Image of trial facility.
Saint Luke's Cancer Institute

Clinical Trials Timothy Pluard is currently running

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Disitamab Vedotin + Tucatinib

for Breast Cancer

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 26 criteria

More about Timothy Pluard

Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Timothy Pluard has experience with
  • Tucatinib
  • Placebo
  • Dapagliflozin
  • T-DM1
  • Nab-sirolimus
  • Trastuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Timothy Pluard specialize in?
Is Timothy Pluard currently recruiting for clinical trials?
Are there any treatments that Timothy Pluard has studied deeply?
What is the best way to schedule an appointment with Timothy Pluard?
What is the office address of Timothy Pluard?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security